-+ 0.00%
-+ 0.00%
-+ 0.00%

Zealand Pharma wins EU approval for Zeydovio to treat short bowel syndrome

PUBT·11/13/2026 15:00:02
Zealand Pharma wins EU approval for Zeydovio to treat short bowel syndrome
  • European Commission grants EU marketing authorization for Zealand Pharma’s Zeydovio (glepaglutide) to treat adults with short bowel syndrome.
  • The company is seeking a partner for global commercialization; a Phase 3 trial supporting US registration is ongoing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130958PRIMZONEFULLFEED1001303531) on November 13, 2026, and is solely responsible for the information contained therein.